低氧诱导因子脯氨酰羟化酶抑制剂治疗慢性肾脏病贫血:欧洲肾脏协会临床实践文件
贫血是慢性肾脏病常见并发症,与不良预后相关。低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)通过模拟低氧反应纠正贫血,已在30多项3期试验中验证疗效,但长期心血管及血栓栓塞安全性待明确。本文详述其作用机制、药理特性及临床定位。
要点
- HIF-PHI通过模拟低氧反应纠正和维持血红蛋白,为ESA替代选择。
- HIF激活除促红细胞生成外,还有降胆固醇、改善铁稳态等效应。
- 长期心血管及血栓栓塞安全性及对肿瘤生长的影响尚需明确。
核心结论
- HIF-PHI为CKD贫血提供ESA之外的替代治疗选择,疗效已在>30项3期试验中证实。
- 长期心血管和血栓栓塞安全性及潜在促肿瘤效应需进一步阐明。
研究设计与样本
- 欧洲肾脏最佳实践委员会(ERBP)制定的临床实践文件,基于现有证据综述HIF-PHI的作用机制、药理特性及在CKD贫血治疗中的地位。
主要发现
- HIF-PHI通过模拟机体低氧反应纠正和维持血红蛋白,已在>30项3期临床试验中显示疗效。
- HIF激活产生多效性作用,包括降低胆固醇、改善铁稳态和潜在抗炎效应。
- CKD贫血患者治疗不足,中重度贫血仍常见,贫血与死亡率、住院、心血管事件及CKD进展风险增加相关,且风险随贫血严重程度增加。
临床怎么用
- HIF-PHI可作为CKD贫血患者使用ESA的替代选择,尤其适用于需要口服药物或存在ESA抵抗等情况。
- 使用HIF-PHI时需关注长期心血管和血栓栓塞风险,并监测潜在肿瘤生长影响。
局限性
- HIF-PHI的长期安全性,特别是心血管和血栓栓塞事件及对肿瘤生长的影响尚未完全明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaemia is a common complication of chronic kidney disease (CKD) and is associated with poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis-stimulating agents (ESAs) and blood transfusions has been the mainstay for treatment of anaemia in CKD for more than 3 decades. Despite available treatments, CKD patients with anaemia are undertreated and moderate-severe anaemia remains prevalent in the CKD population. Anaemia has consistently been associated with greater mortality, hospitalization, cardiovascular events and CKD progression in CKD patients, and the risk increases with anaemia severity. Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors have a novel mechanism of action by mimicking the body's response to hypoxia and have emerged as an alternative to ESAs for treatment of anaemia in CKD. Their efficacy in correcting and maintaining haemoglobin has been demonstrated in >30 phase 3 clinical trials. Additionally, HIF activation results in various pleiotropic effects beyond erythropoiesis, with cholesterol reduction and improved iron homeostasis and potential anti-inflammatory effects. The long-term safety of these agents, particularly with respect to cardiovascular and thromboembolic events, and their possible effect on tumour growth needs to be fully elucidated. This article presents in detail the effects of HIF-PH inhibitors, describes their mechanisms of action and pharmacologic properties and discusses their place in the treatment of anaemia in CKD according to the available evidence.
引用
- Stoumpos S, Crowe K, Sarafidis P, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol Dial Transplant. 2024. PMID: 38573822. doi:10.1093/ndt/gfae075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。